Fulgent Genetics financials
$22.08−1.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M | $421.7M | $32.5M | $21.4M | $18.7M | $18.3M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M | $331.9M | $18.4M | $10.7M | $10.2M | $11.6M |
| Gross margin | 40.6% | 37.8% | 36.1% | 59.3% | 78.3% | 78.7% | 56.6% | 49.9% | 54.3% | 63.2% |
| Operating income | -$91.1M | -$73.9M | -$195.5M | $178.5M | $676.0M | $290.2M | -$428.0K | -$5.1M | -$3.5M | $918.0K |
| Net income | -$60.5M | -$42.7M | -$167.8M | $143.4M | $507.4M | $214.3M | -$411.0K | -$5.6M | -$2.5M | -$13.7M |
| Net margin | −18.8% | −15.1% | −58.0% | 23.2% | 51.1% | 50.8% | −1.3% | −26.3% | −13.4% | −74.8% |
| Diluted EPS | $-1.97 | $-1.41 | $-5.63 | $4.63 | $16.38 | $8.91 | $-0.02 | $-0.31 | $-0.14 | $-1.00 |
| EBITDA | -$67.0M | -$49.0M | -$49.2M | $214.2M | $687.0M | $294.0M | $1.8M | -$2.6M | -$1.4M | $2.2M |
| Operating cash flow | -$101.6M | $21.1M | $27.0M | $253.5M | $538.6M | $140.6M | $5.5M | -$675.0K | $1.3M | $4.4M |
| Free cash flow | -$124.2M | -$19.3M | $4.8M | $234.7M | $514.8M | $105.5M | $4.3M | -$3.0M | -$1.6M | $617.0K |
| Diluted shares | 30.8M | 30.2M | 29.8M | 31.0M | 31.0M | 24.1M | 18.7M | 18.0M | 17.7M | 13.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.2M | $55.1M | $97.5M | $79.5M | $164.9M | $87.4M |
| Short-term investments | $285.9M | $203.0M | $326.7M | $446.7M | $285.6M | $211.9M |
| Total debt | $476.0K | $412.0K | $1.2M | $5.6M | $21.3M | $0.00 |
| Total assets | $1.21B | $1.22B | $1.24B | $1.39B | $1.28B | $700.5M |
| Total liabilities | $106.8M | $90.8M | $102.0M | $116.2M | $112.8M | $131.1M |
| Shareholders' equity | $1.11B | $1.13B | $1.13B | $1.27B | $1.17B | $569.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology